Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oxaliplatin + raltitrexed + pirarubicin
- Development stage
- Unknown
- Lead developer
- Second Affiliated Hospital of Guangzhou Medical University
- Modality
- Small Molecules
- Administration
- Intra-arterial
01
Overview
Oxaliplatin + raltitrexed + pirarubicin is a combination chemotherapy and embolization regimen developed by the Second Affiliated Hospital of Guangzhou Medical University for the treatment of unresectable large hepatocellular carcinoma (HCC). The protocol combines drug-eluting bead transarterial chemoembolization (DEB-TACE) using pirarubicin-loaded microspheres with hepatic artery infusion chemotherapy (HAIC) using the RALOX regimen (oxaliplatin and raltitrexed). Oxaliplatin acts as a DNA alkylating agent, raltitrexed as a thymidylate synthase inhibitor, and pirarubicin as a DNA intercalator and topoisomerase II inhibitor. This intensive local delivery system is designed to improve efficacy in large tumors (>7cm) while reducing the systemic toxicity and infusion time associated with traditional regimens like FOLFOX-HAIC.
- Other names
- RALOX-HAIC + DEB-TACEDEB-TACE + RALOX-HAICoxaliplatin-Second Affiliated Hospital of Guangzhou Medical University-hepatocellular carcinoma
02
Targets
DNATS (Thymidylate synthase)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on oxaliplatin + raltitrexed + pirarubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oxaliplatin + raltitrexed + pirarubicin.